Terms: = Ovarian cancer AND PALB2, ENSG00000083093, 79728 AND Diagnosis
63 results:
1. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
2. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract] [Full Text] [Related]
3. Germline Mutations in 12 Genes and Risk of ovarian cancer in Three Population-Based Cohorts.
Kotsopoulos J; Hathaway CA; Narod SA; Teras LR; Patel AV; Hu C; Yadav S; Couch FJ; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2023 Oct; 32(10):1402-1410. PubMed ID: 37493628
[TBL] [Abstract] [Full Text] [Related]
4. Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.
Møller NB; Boonen DS; Feldner ES; Hao Q; Larsen M; Lænkholm AV; Borg Å; Kvist A; Törngren T; Jensen UB; Boonen SE; Thomassen M; Terkelsen T
Sci Rep; 2023 May; 13(1):8536. PubMed ID: 37237042
[TBL] [Abstract] [Full Text] [Related]
5. palb2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients.
Siraj AK; Bu R; Parvathareddy SK; Iqbal K; Azam S; Qadri Z; Al-Rasheed M; Haqawi W; Diaz M; Victoria IG; Al-Badawi IA; Tulbah A; Al-Dayel F; Ajarim D; Al-Kuraya KS
Sci Rep; 2023 May; 13(1):7666. PubMed ID: 37169825
[TBL] [Abstract] [Full Text] [Related]
6. The association between age at breast cancer diagnosis and prevalence of pathogenic variants.
Daly MB; Rosenthal E; Cummings S; Bernhisel R; Kidd J; Hughes E; Gutin A; Meek S; Slavin TP; Kurian AW
Breast Cancer Res Treat; 2023 Jun; 199(3):617-626. PubMed ID: 37084156
[TBL] [Abstract] [Full Text] [Related]
7. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract] [Full Text] [Related]
8. The impact of coding germline variants on contralateral breast cancer risk and survival.
Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; ; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; ; Jakubowska A; Jung AY; Keeman R; Kristensen VN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mavroudis D; Milne RL; Mulligan AM; Newman WG; Park-Simon TW; Peterlongo P; Pharoah PDP; Rhenius V; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Spurdle AB; Tomlinson I; Truong T; van Veen EM; Vreeswijk MPG; Wang Q; Wendt C; Yang XR; Nevanlinna H; Devilee P; Easton DF; Schmidt MK
Am J Hum Genet; 2023 Mar; 110(3):475-486. PubMed ID: 36827971
[TBL] [Abstract] [Full Text] [Related]
9. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract] [Full Text] [Related]
10. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
[TBL] [Abstract] [Full Text] [Related]
11. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Musacchio L; Califano D; Bartoletti M; Arenare L; Lorusso D; Losito NS; Cormio G; Greggi S; Raspagliesi F; Valabrega G; Salutari V; Pisano C; Spina A; Russo D; Del Sesto M; Canzonieri V; Ferraù F; Zannoni GF; Loizzi V; Ghizzoni V; Casanova C; Tuninetti V; Ducceschi M; Del Vecchio V; Scalone S; Priolo D; Perrone F; Scambia G; Pignata S
Br J Cancer; 2022 Nov; 127(8):1479-1486. PubMed ID: 35869143
[TBL] [Abstract] [Full Text] [Related]
12. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a diagnosis of Epithelial Tubo-ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract] [Full Text] [Related]
13. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract] [Full Text] [Related]
14. Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
Kotsopoulos J; Zamani N; Rosen B; McLaughlin JR; Risch HA; Kim SJ; Sun P; Akbari MR; Narod SA
Br J Cancer; 2022 Sep; 127(5):879-885. PubMed ID: 35710751
[TBL] [Abstract] [Full Text] [Related]
15. palb2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina.
Gonzalez A; Del Greco F; Vargas-Roig L; Brun B; Tabares G; Mampel A; Montes C; Martin C; Lopez M; Rossi N; Bruno L; Ponce C; Quaglio P; Yanzi A; Acevedo S; Lugo L; Lopez Breccia P; Avila S; Sisterna S; Del Castillo MS; Vazquez M; Nuñez LM
Breast Cancer Res Treat; 2022 Jul; 194(2):403-412. PubMed ID: 35610400
[TBL] [Abstract] [Full Text] [Related]
16. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract] [Full Text] [Related]
17. Detection of a pathogenic Alu element insertion in palb2 gene from targeted NGS diagnostic data.
Eyries M; Ariste O; Legrand G; Basset N; Guillerm E; Perrier A; Duros C; Cohen-Haguenauer O; de la Grange P; Coulet F
Eur J Hum Genet; 2022 Oct; 30(10):1187-1190. PubMed ID: 35277653
[TBL] [Abstract] [Full Text] [Related]
18. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast cancer Susceptibility Genes.
; Mavaddat N; Dorling L; Carvalho S; Allen J; González-Neira A; Keeman R; Bolla MK; Dennis J; Wang Q; Ahearn TU; Andrulis IL; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Briceno I; Brüning T; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Christiansen H; Czene K; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; Geisler J; Giles GG; Guénel P; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Hartikainen JM; Hartman M; Hoppe R; Howell A; Jakubowska A; Jung A; Khusnutdinova EK; Kristensen VN; Li J; Lim SH; Lindblom A; Loizidou MA; Lophatananon A; Lubinski J; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Morra A; Muir K; Obi N; Osorio A; Park-Simon TW; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Thorne H; Tomlinson I; Torres D; Truong T; Yip CH; Spurdle AB; Vreeswijk MPG; Dunning AM; García-Closas M; Pharoah PDP; Kvist A; Muranen TA; Nevanlinna H; Teo SH; Devilee P; Schmidt MK; Easton DF
JAMA Oncol; 2022 Mar; 8(3):e216744. PubMed ID: 35084436
[TBL] [Abstract] [Full Text] [Related]
19. Hereditary pancreatic cancer.
Abe K; Kitago M; Kitagawa Y; Hirasawa A
Int J Clin Oncol; 2021 Oct; 26(10):1784-1792. PubMed ID: 34476650
[TBL] [Abstract] [Full Text] [Related]
20. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast cancer.
Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H
Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423
[TBL] [Abstract] [Full Text] [Related]
[Next]
